A study in the Emerging Infectious Diseases journal shows treating 20% of COVID-19 patients with Paxlovid could save up to 0.85 million lives and reduce the economic burden by US $170.17 billion in the US.
Study reveals robust memory T-cell responses to SARS-CoV-2 in healthcare workers over 1.5 years post-Omicron, suggesting durable immunity against highly mutated variants.